The hypothesis that increased oxidative stress in breast cancer (BC) patients could induce enhanced lipid peroxidation, which, in turn, would contribute to platelet activation and poor clinical outcome is attractive. To address this issue, we investigated presurgical urinary 8-iso-prostaglandin (PG)F 2a (marker of in vivo oxidative stress) and 11-dehydro-thromboxane (TX)B 2 (marker of in vivo platelet activation) levels in patients with primary BC (n 5 115) compared with control women paired for comorbidities and their association with patients' metabolic profile and clinical prognostic factors. The results obtained showed that presurgical urinary excretion of both biomarkers was enhanced in BC patients compared to controls and was associated with patients' estrogen receptor (ER) expression, but not HER2 status or Ki67 proliferation index. Accordingly, both urinary biomarkers were increased in patients with luminal-like BC molecular subtypes compared with triple negative or HER2-enriched tumors. ER status was an independent predictor of 8-iso-PGF 2a urinary levels, which, in turn, significantly predicted 11-dehydro-TXB 2 urinary levels together with disease stage and ER status. The prognostic value of 11-dehydro-TXB 2 was then evaluated showing a significant correlation with BC pathological response to neoadjuvant treatment. Furthermore, among relapsing patients, those with elevated urinary biomarker levels were more likely to develop distant metastasis rather than local recurrence. In conclusion, we may speculate that enhanced oxidative stress due to estrogen-related mechanisms might cause a condition of persistent platelet activation capable of sustaining BC growth and progression through the release of bioactive stored molecules, ultimately contributing to tumor invasiveness. Further studies specifically addressing this hypothesis are presently needed.
Introduction
Breast cancer (BC) is the most common female cancer and the second leading cause of cancer-related death in women, worldwide. Its etiology is multifactorial and related to various risk factors, including advanced age, early menstruation, late menopause, use of oral contraceptives and metabolic derangement after menopause. Accordingly, recent data have clearly demonstrated that type 2 diabetes (T2D) and obesity are among the most important risk factors for postmenopausal estrogen-dependent BC, also suggesting that oxidative stress might represent a shared mechanism for BC initiation and/or progression. 1, 2 The hypothesis of a link between metabolic disorders, oxidant stress and BC risk is substantiated by clinical data derived from two large studies providing direct biochemical evidence that urinary markers of lipid peroxidation 3, 4 or oxidative DNA damage 3 may be associated with increased BC risk, mostly among overweight women. 4 Noteworthy, oxidant stress and enhanced lipid peroxidation are also key players in the initiation of persistent platelet activation both in T2D and in obesity. [5] [6] [7] Platelets, in turn, play a fundamental role in cancer progression, as strongly suggested by recent experimental and epidemiological studies in human cancers, [8] [9] [10] including BC. 11 Thus, based on the available body of evidence, we hypothesized that increased oxidative stress in BC patients could induce enhanced lipid peroxidation, which, in turn, could contribute to platelet activation and poor clinical outcome.
To address this issue, we set out to investigate whether urinary 8-iso-prostaglandin (PG)F 2a (a secondary end product of lipid peroxidation and a reliable marker of in vivo oxidative stress 12 ) prior to surgery is increased in patients with primary BC when compared with obesity-and T2D-matched women without cancer and whether it correlates with the rate of 11-dehydro-TXB 2 urinary excretion (a reliable marker of in vivo platelet activation 13 ). Association with the patient metabolic profile and selected lifestyle factors was also performed. Furthermore, since BC is a highly heterogeneous disease, characterized by different prognosis and treatment options, depending on ER/PR status and HER2/NEU (human epidermal growth factor receptor 2) expression, we analyzed the possible associations of both metabolites in subgroups of patients characterized by more aggressive tumor phenotypes. Secondary endpoint was the evaluation of the prognostic value of both urinary markers either in terms of pathological response to neoadjuvant treatment or in regards to relapsing disease.
Methods

Patients
Currently, the PTV Bio.Ca.Re. (Policlinico Tor Vergata Biospecimen Cancer Repository) and the Interinstitutional Multidisciplinary Biobank of the IRCCS San Raffaele Pisana (BioBIM, Rome, Italy) are involved in the recruitment of ambulatory cancer patients with primary or metastatic BC, who are prospectively followed under the appropriate Institutional ethics approval, as part of a Clinical Database and Biobank project. In these facilities, all patients provide written informed consent, previously approved by the local Institutional Review Board, to donate biological samples to be used in the analysis of possible determinants of BC outcome or response to treatment. All samples are processed, aliquoted, coded, and stored at 2808C using standard operating procedures and informatics tools to track the entire sample life. 14, 15 Storage conditions are carefully monitored, and all aliquots are limited to one freeze-thaw cycle to ensure the best sample quality. Among all collected samples, urine and matched blood samples were available from 115 consecutive BC patients, who represented the final study cohort. BC was pathologically staged according to the TNM classification. Seventeen (15%) women received neoadjuvant chemotherapy. All patients underwent radical surgery (64% conservative surgery, 36% mastectomy). Concurrent adjuvant radiotherapy was instituted in 57 patients. Adjuvant anthracycline-based regimens were administered in 32 (28%) women. Fifty-eight women underwent adjuvant endocrine therapy only (tamoxifen, n 5 26, or aromatase inhibitor, n 5 32). Patients with HER2/ NEU positivity were all treated with trastuzumab-containing regimens. None of the participants had taken vitamin supplements, aspirin, nonsteroidal anti-inflammatory drugs, or other antiplatelet agents in the 2 weeks before blood withdrawal. Patients' characteristics are summarized in Table 1 . One hundred fifteen unrelated women from the same geographical area of the patients, paired for obesity and T2D occurrence were recruited as control group.
Sample collection and laboratory measurements
Fasting blood samples were withdrawn without stasis from each recruited subject from the antecubital vein, using a 20G needle, after a rest period of at least 20 min. Overnight urine samples were collected before blood sampling from each recruited woman. Samples from all BC patients were obtained at baseline prior to any treatment.
Routine chemistry studies, including fasting blood glucose, were performed on fresh samples within one hour from blood withdrawal on an ARCHITECT c8000 System (Abbott Laboratories, Abbott Park, IL, USA). Fasting insulin levels were analyzed on serum samples using a fully automated Lumipulse G 600 II chemiluminescent enzyme immunoassay analyzer (Fujirebio, Tokyo, Japan) according to the manufacturer's instructions. The homeostasis model assessment (HOMA) index (a marker of insulin resistance) was calculated for each participating subject from fasting blood glucose and insulin according to the formula: glucose [mg/dl] 3 insulin [lIU/ml]/405). 16 HbA 1C levels were measured by automated HPLC (Tosoh Bioscience, Rivoli, TO, Italy). Urinary 8-iso-PGF 2a and 11-dehydro-TXB 2 were measured on first morning urine specimens by previously described radioimmunoassays. 17, 18 Both markers were adjusted for creatinine concentrations and expressed as pg/mg of creatinine. Interassay and intra-assay variations of both measurements (average of duplicates) were <10%. Measurements were ascertained while blinded to the sample origin.
What's new?
The hypothesis that increased oxidative stress in breast cancer (BC) patients could induce enhanced lipid peroxidation, which, in turn, would contribute to platelet activation and poor clinical outcome is attractive. Here, the authors found that enhanced oxidative stress due to estrogen-related mechanisms might cause a condition of platelet activation (as evidenced by enhanced 11-dehydro-thromboxane B 2 urinary excretion levels) capable of sustaining BC growth and progression, ultimately contributing to tumor invasiveness. Determination of 11-dehydro-thromboxane B 2 urinary excretion prior to treatment might improve risk stratification in selected categories of patients, i.e., those with locally advanced luminal-like BC molecular types undergoing neoadjuvant treatment.
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Assessment of prognostic indexes
Immunohistochemical analyses were performed on formalinfixed, paraffin-embedded tumor sections for hormone receptor 19 and HER2/NEU expression or proliferation index (Ki67). HER2/NEU positivity was defined according to the American Society of Clinical Oncology-College of American Pathologists (ASCO-CAP) guidelines as an immunohistochemical staining of 31 or 21 with evidence of gene amplification at FISH. 20 Immunohistochemical detection of Ki67 was performed on the Ventana BenchMark XT automated staining platform (Roche Diagnostics GmbH, Mannheim, Germany) according to manufacturer's instructions. Ki67 proliferative index in surgical specimens was assigned by the pathologist on the basis of the percentage positive on at least 500 neoplastic cells counted in the peripheral area of the nodule. A cutoff value of 20% was used in all association analyses, according to the recommendations of the St Gallen International Expert Consensus on the primary therapy of early BC 2013. 21 
Statistical analysis
Sample size of the study was based on sample availability and willingness to provide informed consent rather than on sample size calculations. However, estimation was later performed and showed that, given the observed means for patients (l 1 ) and control (l 2 ) groups for 11-dehydro-TXB 2 (or 8-iso-PGF 2a ) and using a type I error probability of 0.05, the recruited population yielded a statistical power >90%.
Data are presented as percentages, mean (SD), or median and interquartile range (IQR). Student's unpaired t test and ANOVA test were used for normally distributed variables. Appropriate nonparametric tests (Mann-Whitney U test and Kruskal-Wallis ANOVA and median test) were employed for all the other variables. Multiple linear regression analyses were performed to quantify the relationship between urinary biomarkers and BC clinical features. For administrative censoring, follow-up was ended the date of May 31, 2016. Progression-free survival (PFS) curves were calculated by Kaplan-Meier and log-rank methods. Statistical analyses were performed using a computer software package (Statistica 8.0, StatSoft, Tulsa, OK). All tests were two-tailed and only p values lower than 0.05 were regarded as statistically significant.
Results
Presurgical urinary excretion of both 8-iso-PGF 2a and 11-dehydro-TXB 2 was enhanced in BC patients compared to obesity-and T2D-paired control women [both p < 0.0001] ( Table  2) (Figs. 1a and 1b) . Urinary 8-iso-PGF 2a and 11-dehydro-TXB 2 directly correlated at univariate analysis both in BC patients (Spearman rank test, R s 5 0.235, p 5 0.011) and control women (R s 5 0.720, p < 0.0001) (Fig. 1c) . No significant associations were observed between either 8-iso-PGF 2a or 11-dehydro-TXB 2 and menopausal status, smoking habit, degree of physical activity, overweight/obesity, T2D, hypertension or dyslipidemia in BC patients (data not shown).
Of interest, both urinary biomarkers directly correlated with BC patients' estrogen receptor (ER) expression (8-iso-PGF 2a , R s 5 0.236, p 5 0.011; 11-dehydro-TXB 2 , R s 5 0.245, p 5 0.008), whereas urinary 11-dehydro-TXB 2 excretion (R s 5 0.228, p 5 0.014), but not 8-iso-PGF 2a (R s 5 0.129, p 5 0.171) correlated with progesterone receptor (PR) status. Accordingly, BC patients with negative ER/PR had significantly lower levels (Figs. 2a  and 2b ). No significant association was observed between both urinary metabolite excretion and either HER2/NEU status or Ki67 proliferation index. Consequently, significantly increased presurgical urinary excretion of either 8-iso-PGF 2a or 11-dehydro-TXB 2 were observed in patients with luminal-like A (LLA) or luminal-like B (LLB) BC molecular subtypes compared with triple negative breast cancer (TNBC) or HER2-enriched tumors (Figs. 2c and 2d) .
The association between 8-iso-PGF 2a or 11-dehydro-TXB 2 and stage of disease was finally analyzed. Overall there was no association between presurgical urinary excretion of 8-iso-PGF 2a and BC stage, whereas a weak, but significant association was observed for 11-dehydro-TXB 2 (Kruskal-Wallis H 5 6. To further assess the association among urinary biomarkers and clinical and metabolic features of BC patients, multivariate regression analyses were performed by forward stepping. The results obtained showed that the HOMA index (p 5 0.023) and ER status (p 5 0.049) were both predictors of 8-iso-PGF 2a urinary excretion levels, independently of age, stage, HER2/NEU, Ki67 proliferation index, body mass index (BMI), and HbA 1c (Table 3) . BC stage (p 5 0.010), 8-iso-PGF 2a (p 5 0.015) and ER status (p 5 0.054), in turn, significantly predicted 11-dehydro-TXB 2 urinary excretion levels, independently of the other tested variables (Table 3) .
Relationship of urinary biomarkers with neoadjuvant treatment outcome
Pathologic response to neoadjuvant chemotherapy was graded according to Miller and Paine. 22 Of the 17 BC women treated, (Fig. 3a) . No significant difference was observed for 8-iso-PGF 2a among different responders, though this might be due to the small sample size.
Recurrence rates and survival outcomes
Clinical follow-up is currently ongoing. At the time of administrative censoring, 100 (87%) patients were clinically free of disease over a 3-year median follow-up. Fourteen (12%) patients had relapsing disease, 6 had local recurrence (2 died of disease), and 8 had distant metastasis (2 died of disease); 7 patients (6 with distant metastasis) were alive with disease at time of study end. One (1%) patient had a second primary breast carcinoma after 26 months; this patient was censored as free of disease at the time of clinical diagnosis. Of interest, patients who developed distant metastases had significantly higher 11-dehydro-TXB 2 urinary excretion levels than patients who had local recurrence (1,467 vs. 2,354 pg/mg of creatinine, p 5 0.020) (Fig. 3b) . Accordingly, when BC patients were dichotomized on the basis of an arbitrary cutoff calculated on the median 11-dehydro-TXB 2 level observed in the overall population, the survival rate of patients living without disease was higher in patients with low urinary excretion rates compared with patients with high 11-dehydro-TXB 2 urinary excretion levels (98 vs. 67%; log-rank test 5 1.81, p 5 0.070). 
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Discussion
Despite the availability of clinical and experimental data in support of an active involvement of the haemostatic system in cancer dissemination and progression, 9 our current understanding of the role of platelets in BC progression is still modest. 11 Increased platelet activation has been occasionally reported in BC patients, but clinical data are limited and the association with clinical-pathological features in BC is controversial, mostly depending on the biomarker used in the analysis. [23] [24] [25] [26] [27] [28] Indeed, pre-activation due to methodological pitfalls is one of the major risks when analyzing platelet-derived biomarkers, 29 a possibility that together with an inaccurate choice of controls (as in vivo platelet activation can occur in obese women, or with T2D [5] [6] [7] ) might have underpowered many of the studies. 
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Here, we report the results obtained in a cohort of BC women in whom platelet activation was assessed by measurement of 11-dehydro-TXB 2 urinary excretion levels. This is one of the most abundant TXB 2 metabolites and, owing to its kinetics, it has been suggested to provide a time-integrated index of endogenous systemic TXA 2 biosynthesis, allowing evaluation of ongoing platelet activation. 29 Using this marker, we demonstrated, for the first time to our knowledge, that in vivo platelet activation is enhanced in patients with BC compared with obesity-and diabetes-paired control women. Major finding of our study was a significant association between in vivo platelet activation and BC invasiveness, as demonstrated by the occurrence of lower pre-surgical 11-dehydro-TXB 2 urinary excretion levels in DCIS compared with both early and advanced BC stages. This is in agreement with the results obtained by Toth et al. who demonstrated that platelet-derived microparticles (PMP, released upon activation) were higher in BC patients with larger tumor size (T2) and differed significantly from patients with T1 or in situ tumors, an observation that led the authors to speculate that PMP might be active players in the tumor microenvironment. 26 Indirect evidence of the role of platelet activation in BC invasiveness in our study could be also derived by the observation that 11-dehydro-TXB 2 urinary excretion levels correlated with BC pathological response to neoadjuvant treatment. Furthermore, among relapsing patients, those with elevated urinary biomarker levels were more likely to develop distant metastasis rather than local recurrence. Accordingly, the survival rate of patients living without disease was higher in women with low compared with women with high 11-dehydro-TXB 2 urinary excretion levels. All together, these findings corroborate the experimental hypothesis of a direct role of platelets in tumor growth and metastasis.
Of interest, presurgical urinary excretion levels of 11-dehydro-TXB 2 were not only associated with the stage of disease, but ER and patients' oxidant status were also independent predictors of persistent platelet activation at multivariate analysis. On the other hand, ER status also predicted 8-iso-PGF 2a levels, which supports the chance of a feedback loop in BC patients, although the possibility that ER status can both predict and be predicted by 8-iso-PGF 2a and 11-dehydro-TxB 2 levels cannot be proved in the present study. Nonetheless, these observations are consistent with previous findings from our group demonstrating that oxidant stress and enhanced lipid peroxidation are key players in the initiation of persistent platelet activation in various clinical settings, including T2D and obesity. [5] [6] [7] Here we provide evidence of the occurrence of a pro-oxidant status (as reflected by increased 8-iso-PGF 2a urinary excretion levels) in BC women, which was independently associated to insulin resistance (a key feature of T2D and obesity) and hormone receptor status. While insulin resistance has been proposed as a pathogenetic mechanism linking obesity, T2D, and BC, 2 the finding of enhanced lipid peroxidation in BC is in agreement with previous findings demonstrating the occurrence of elevated levels of urinary isoprostanes in patients with invasive BC. 30 Furthermore, higher oxidative stress was found in ER(1) compared with ER(2) BC patients, as previously suggested. 31 In line with the hypothesis of an estrogen-induced oxidative stress, patients with TNBC had a reduced oxidant status compared with luminal-like subtypes, as demonstrated by lower levels of 8-iso-PGF 2a urinary excretion in our study population, as well as 8-hydroxydeoxyguanosine (8-OHdG) 32 or malondialdehyde (MDA) 33 in other studies. HER2-enriched BC were also characterized by lower levels of urinary 8-iso-PGF 2a , partially confirming previous results of decreased MDA-but not 8-isoprostane F2-levels in HER2(1) BC, a finding that led the authors to suggest that HER2 overexpression may protects against plasma lipoperoxidation.
34
Albeit estrogens can act as complete carcinogens, the possibility that their mechanism(s) of action may involve the induction of redox-sensitive signaling pathways has been only recently acknowledged 35, 36 and it has been hypothesized that, if sustained, oxidative stress might cause estrogen independence and aggressive growth behavior, 37 potentially through epigenetic silencing of ER expression. 38 The finding here reported adds another possible mechanism, in which redox-induced persistent platelet activation might contribute to BC invasiveness through the release of several bioactive stored molecules (growth factors, proangiogenic cytokines, etc.), all capable of sustaining BC growth and progression.
Finally, the interindividual variability in the extent of lipid peroxidation and platelet activation associated with ER status and disease stage, needs to be acknowledged in the interpretation of the available literature regarding the efficacy of aspirin in breast cancer progression and invasiveness. 39, 40 In this regard, urinary 11-dehydro-TXB 2 excretion may represent a valuable biomarker for identifying appropriate candidates for effective aspirin use in future clinical trials.
All these hypotheses require detailed experimental evaluation before their ultimate significance can be determined, and there are, of course, some limitations to our study that need to be acknowledged. The most obvious resides in the relatively small sample size (especially in subgroup analyses, as in the case of the neoadjuvant setting). Moreover, recruitment was monoinstitutional, which might have posed further limitation in terms of external validity. Finally, the study was a retrospective analysis, although all eligible consecutive patients were prospectively included. Among the limitation to be taken into consideration is that our study was not designed to provide information on the possible TXA 2 production by tumor cells. Indeed, an increased biosynthesis of prostanoids in BC tissues has been previously reported, suggesting that the cancer cells themselves are capable of releasing TXB 2, 41, 42 although the relative contribution by the tumor, or the host inflammatory cells unavoidably associated with cancer (including platelets), cannot be determined with the present data. On the other hand, the strength of our analysis is represented by the use of samples collected and processed using standard operating procedures in the context of a large Biobank, which minimized the difference in sample analyses, as well as the systematic laboratory and clinical characterization of the subjects enrolled, paralleled by adequate, matched controls.
In conclusion, it is intriguing to speculate that enhanced oxidative stress due to insulin resistance and/or to estrogenrelated mechanisms (acting through ER-mediated pathways) might cause a condition of persistent platelet activation capable of sustaining BC growth and progression through the release of bioactive stored molecules, ultimately contributing to tumor invasiveness in BC patients. Further multicenter prospective studies involving a larger number of patients are presently needed before the ultimate prognostic significance of platelet activation in BC can be established.
